BRIEF-Abiomed's Impella CP receives expanded FDA approval for high-risk PCI procedures
December 07, 2016 at 07:24 AM EST
* Abiomed Impella CP receives expanded FDA approval for high-risk percutaneous coronary intervention (PCI) procedures Source text for Eikon: Further company coverage:
